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Introduction
Th  e ability of primary tumor cells to disseminate and 
metastasize depends on their genetic and epigenetic 
alterations as well as the microenvironmental cues they 
receive. New molecular technologies, such as DNA micro-
arrays, have identiﬁ  ed a variety of molecules that contri-
bute to the development of metastasis. Th  ese  molecules 
include growth factors, cytokines and chemokines, pro-
angiogenic factors, extracellular matrix-remodeling mole-
cules, several epithelial–mesenchymal transition (EMT)-
inducing transcription factors, as well as certain miRNAs 
[1-3]. Understanding of the molecular and cellular 
determinants of metastasis, however, is still limited. 
Moreover, current prognostic markers of many cancers, 
including primary breast carcinomas, only poorly predict 
eventual metastatic progression [4]. For these reasons, 
critical regulators of the metastatic process that have 
implications for diagnosis, prognosis, and treatment – 
including proteins, and small and large noncoding RNAs – 
continue to be highly sought.
miRNAs are small noncoding RNA molecules that bind 
to perfect or imperfect complementary sequences at the 
3’ UTR of target mRNAs, leading to either mRNA 
degrada  tion or inhibition of their translation, or both [5]. 
In an initial screen for miRNAs diﬀ  erentially expressed in 
human breast cancer cells, the three most signiﬁ  cantly 
upregulated miRNAs miR-155, miR-9, and miR-10b were 
identiﬁ  ed [6].
miR-10b is a particularly interesting candidate given its 
close correlation with metastatic behaviors. Th  e  subse  quent 
functional studies of miR-10b validated its can  didacy as a 
mechanistically important miRNA, as demon  strated by in 
vivo experiments showing that overexpression of miR-
10b in otherwise nonmetastatic breast tumors triggered 
tumor invasion and distant metastasis in xenotrans-
plantation models [6]. Th  ese ﬁ  ndings provided the ﬁ  rst 
evidence that overexpression of a speciﬁ  c miRNA can 
contribute to the development of metastasis. Conversely, 
therapeutic silencing of miR-10b with antagomirs sup-
pressed metastasis in a mouse mammary tumor model 
[7]. Further studies are needed to address the remaining 
questions, including: Does miR-10b play a role in normal 
development and in progression of spontaneous breast 
cancer? At which stage and in which subset of tumor cells 
is miR-10b expression activated? Which clinical cancers 
would respond to inhibition of miR-10b?
miR-10b expression correlates with high-grade 
malignancy and metastatic behaviors
miR-10b was ﬁ  rst identiﬁ  ed as a miRNA that is highly 
expressed speciﬁ   cally in metastatic breast cancer cell 
lines – cell lines that are capable of launching metastases 
when growing as primary mammary tumors in mice. 
When compared with normal human mammary epi-
thelial cells, metastatic cell lines MDA-MB-231 and 
SUM1315 exhibit 50-fold higher miR-10b expression 
levels [6]; in contrast, nonmetastatic breast cancer cell 
lines SUM149, SUM159, and MCF-7 express lower 
miR-10b levels than human mammary epithelial cells [6]. 
Th  is expression pattern was conﬁ   rmed and further 
extended by an independent study [8]. In addition, miR-
10b is among the most signiﬁ  cantly upregulated miRNAs 
in the 4T1 metastatic mouse mammary tumor cell line 
relative to its nonmetastatic or poorly metastatic isogenic 
relatives (67NR, 168FARN, and 4TO7) [9].
Abstract
Ninety percent of cancer-related mortality is caused 
by metastasis. Current cancer treatments can control 
many primary tumors but rarely stop the metastatic 
spread. Accumulating evidence demonstrates 
that miRNAs are involved in cancer initiation and 
progression. Furthermore, several miRNAs have been 
found to regulate metastasis. In particular, recent 
studies provide the fi  rst functional evidence that 
overexpression of a specifi  c miRNA, miR-10b, can 
contribute to the development of metastasis, which 
can be exploited therapeutically in treating breast 
cancer metastasis in mice. Further in-depth analysis 
should provide more precise evaluation of the roles, 
mechanisms, and therapeutic utility of this miRNA in 
breast cancer.
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were ﬁ  rst examined in 23 advance-stage breast cancer 
patients whose tumor samples were obtained at the time 
of mastectomy: relative to normal mammary tissues, the 
level of this miRNA is lower in primary breast tumors 
isolated from metastasis-free patients, while 50% of 
metastasis-positive patients show elevated miR-10b 
levels in their breast tumors [6]. On the other hand, 
miR-10b expression levels in unfractionated bulk cell 
popu  lations of tumors removed from early-stage breast 
cancer patients do not predict future metastatic recur-
rence [10]. It may not be informative, however, to make a 
prognosis based on expression analysis performed on the 
heterogeneous cell populations within early-stage primary 
tumors, in which metastatic cells may not be present or 
may represent only a rare subset of the total tumor mass.
In advance-stage tumors, miR-10b expression indeed 
correlates with high-grade malignancy in various cancer 
types. Higher levels of miR-10b were observed in meta-
static samples relative to matched primary tumors [11]. 
Another study reported that miR-10b is upregulated in 
hepatocellular carcinomas from metastasis-positive 
patients compared with hepatocellular carcinomas from 
metastasis-free patients [12]. In addition, miR-10b is one 
of the top upregulated miRNAs in human pancreatic 
adenocarcinomas [13] and glioblastomas [14,15], two 
types of highly metastatic and/or invasive cancers. In 
human gliomas, miR-10b levels correlate with tumor 
grade, invasiveness, and levels of the tumor invasive 
factors urokinase  plasminogen activator receptor and 
RhoC [16]. Compared with normal Schwann cells, 
miR-10b is markedly upregulated in tumor tissues from 
malignant peripheral nerve sheath tumors and in 
Schwann cells isolated from neuroﬁ   bromatosis type 1 
(NF1) neuro  ﬁ  bromas [17].
miR-10b functionally contributes to tumor invasion 
and metastasis
Overexpression of miR-10b can endow cancer cells with 
invasive and metastatic abilities in vivo. Th  e  ﬁ  rst evidence 
came from overexpression analyses in two xenograft 
models. In both cases, human breast carcinoma cells 
were implanted into the mammary fat pads of 
NOD-SCID mice. In the SUM149 model, at 6 weeks post 
implantation, the control tumors were non-invasive, as 
evidenced by their conﬁ  nement within ﬁ  brotic capsules; 
in contrast, the miR-10b-expressing SUM149 tumors 
displayed substantial invasion, with islands of carcinoma 
cells that invaded the stroma [6]. From 9 weeks, the lungs 
of mice bearing miR-10b-expressing tumors, but not the 
control tumors, showed clusters of micrometastatic cells, 
as evidenced by cytokeratin immunostaining. In another 
otherwise nonmetastatic human breast cancer cell line, 
the SUM159 line, ectopic expression of miR-10b led to 
more visible signs of lung metastases as well as macro-
scopic peritoneal metastases [6]. Th  ese results suggest 
that miR-10b is a metastasis-promoting miRNA in vivo 
in breast cancer.
miR-10b is also involved in the progression of other 
types of cancer. Antisense silencing of miR-10b in NF1 
malignant peripheral nerve sheath tumor cells reduced 
cell proliferation, migration and invasion [17]. In 
esophageal cancer cells, ectopic expression of miR-10b 
increased cell motility and invasiveness, whereas inhibi-
tion of miR-10b reduced cell invasiveness [18]. When 
miR-10b was overexpressed in nasopharyngeal carci-
noma cells, it markedly induced the cells’ in vitro migra-
tion and invasion, as well as in vivo metastasis formation 
in nude mice [19]. Although the role of miR-10b in 
pancreatic cancer has not yet been reported, miR-10a – 
which shares the same seed sequence as miR-10b, and 
diﬀ  ers from miR-10b by a single nucleotide – has been 
reported to be a metastasis-promoting miRNA in pan-
creatic cancer cells [20].
Regulation of expression and molecular 
mechanisms of miR-10b action
In breast cancer cells, miR-10b levels correlate not only 
with metastatic potential, but also with expression levels 
of the EMT-inducing, metastasis-promoting transcrip  tion 
factor Twist [6]. Th   is association has also been extended 
in other types of cancer. For instance, in a collection of 46 
head and neck squamous cell carcinomas, miR-10b and 
Twist were found to be highly correlated (P = 0.006) [21].
Twist is a pleiotropic transcription factor [22]. Among 
its multiple targets, Twist activates the transcription of 
the  mir-10b gene (Figure 1)     by binding directly to an 
E-box sequence proximal to its putative promoter [6]. 
Although the miR-10b miRNA does not trigger an EMT 
by itself, it appears to be required for Twist-induced cell 
motility and invasiveness in human mammary epithelial 
cells [6], suggesting that miR-10b is a mediator of some 
elements of the multicomponent, Twist-induced EMT 
program, but not an inducer of EMT on its own.
Similar to other pleiotropically acting factors (for 
example, transcription factors), each miRNA can func-
tion through regulating the expression of many target 
mRNAs, particularly through one or a few key target 
mRNAs. In mammary epithelial cells and breast carci-
noma cells, miR-10b can directly suppress the translation 
of HOXD10, an mRNA encoding a transcriptional repres-
sor that inhibits expression of several genes involved in 
cell migration and extracellular matrix re  model  ing, such 
as RhoC, urokinase plasminogen activator receptor, α3-
integrin, and MT1-MMP (Figure 1) [6]. Interestingly, 
HOXD10 is not only targeted by the miR-10b miRNA, 
but also targeted by a long noncoding RNA termed 
HOTAIR, which has also been shown to promote breast 
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reprograms the chromatin state, causing increased 
Polycomb repressive complex-2 occupancy on promoters 
of genes that inhibit breast cancer progression, including 
HOXD10 [23]. On the other hand, miR-10b could also 
suppress the expression of T-lymphoma invasion and 
metastasis-1, a guanidine exchange factor for Rac, in the 
SUM159 breast cancer cell line [24]. Th  e eﬀ  ect of miR-
10b on metastatic behaviors of cancer cells is thus most 
likely to be a consequence of regulating multiple target 
mRNAs expressed in these cells. Th  is is analogous to 
other cancer genes that regulate the expression of 
numerous target genes with either similar or opposing 
functions, such as the oncogene MYC, which can activate 
both pro-survival and pro-apoptotic genes [25].
Several independent groups have further conﬁ  rmed the 
Twist–miR-10b–HOXD10–RhoC pathway and demon-
strated that this pathway is regulated by known cancer 
gene products (Figure 1). One study revealed that ectopic 
expression of the breast cancer metastasis suppressor-1 
gene, a negative regulator of Twist expres  sion, leads to 
downregulation of miR-10b and RhoC, as well as 
upregulation of HOXD10, in highly metastatic breast 
tumor cells [8]. Another group reported that this pathway 
is positively regulated by CD44 and Src: binding of 
hyaluronan to CD44 leads to c-Src kinase activation, 
which in turn activates Twist through phosphorylation 
and nuclear translocation. Further analyses demonstrated 
that miR-10b is controlled by the Twist binding site in its 
promoter region, and that induction of miR-10b expres-
sion by hyaluronan/CD44-activated c-Src in breast cancer 
cells is Twist dependent. Th   is leads to down  regu  lation of 
HOXD10, RhoA/RhoC upregulation, Rho-kinase activa-
tion and breast cancer cell invasion [26]. A third study 
showed that miR-10b is highly expressed in Epstein–Barr 
virus-positive, latent membrane protein-1 (LMP1)-
expressing, metastatic nasopharyngeal carcinoma cells 
relative to LMP1-negative, nonmetastatic nasopharyn-
geal carcinoma cells, and is downregulated in response to 
silencing either LMP1 or Twist. Moreover, LMP1 
expression leads to induction of miR-10b, which is Twist 
dependent [19].
Other targets of miR-10b have been identiﬁ  ed  in 
various tumor cell types. For instance, miR-10b can 
directly target the mRNA of the tumor suppressor 
neuroﬁ  bromin in NF1 malignant peripheral nerve sheath 
tumor cells, indicating that this miRNA might play an 
important role in NF1 tumor formation and progression 
through silencing neuroﬁ   bromin and activating RAS 
signaling in these cells (Figure 1) [17]. Th   is also illustrated 
a new mechanism (in addition to NF1 loss of hetero-
zygosity, unequal expression of NF1 alleles, NF1 mRNA 
editing, and so forth) for downregulating the NF1 tumor 
suppressor in tumors suﬀ  ering from NF1 heterozygosity. 
Moreover, KLF4 – a transcription factor with context-
dependent oncogenic or tumor-suppressor functions 
[27,28] that has been reported to inhibit esophageal 
cancer cell migration and invasion – has been identiﬁ  ed 
as a direct target of miR-10b in esophageal squamous cell 
carcinoma cells (Figure 1) [18]. Similar to other miRNAs, 
the precise function of miR-10b may be tissue speciﬁ  c, 
which at least in part depends on the expression pattern 
of its target mRNAs in a given cell type.
miR-10b is a potential target for anti-metastasis 
therapeutic approaches
Targeting metastasis-promoting miRNAs may represent 
a novel therapeutic strategy for breast cancer treatment. 
Among several types of in vivo miRNA antagonists being 
developed are antagomirs – a type of chemically 
engineered, cholesterol-conjugated antisense RNA oligo-
nucleotide [29,30]. Th  e  eﬀ  ect of the miR-10b antagomir 
(termed antagomir-10b) was tested in a 4T1 mouse 
mammary tumor metastasis model: systemic delivery of 
antagomir-10b had a potent and highly speciﬁ  c 
Figure 1. miR-10b-mediated pathways in regulating tumor 
progression and metastasis. Multiple cancer gene products – 
including breast cancer metastasis suppressor-1 (BRMS1), latent 
membrane protein-1 (LMP1), CD44 and c-Src – regulate Twist 
expression. Among its multiple downstream targets/eff  ectors, 
elevated expression of the transcription factor Twist in breast cancer 
cells induces the transcription of miR-10b. This miRNA suppresses 
synthesis of the HOXD10 protein, a negative regulator of breast 
cancer progression, permitting expression of pro-metastatic gene 
products, RhoC, urokinase plasminogen activator receptor (uPAR), 
α3-integrin, and MT1-MMP. This in turn favors cancer cell migration, 
invasion, and metastasis. Expression of HOXD10 is also inhibited 
by a long noncoding, metastasis-promoting RNA named HOTAIR. 
In addition, miR-10b targets KLF4 in esophageal cancer cells, 
leading to increased migration and invasion. In neurofi  bromatosis 
type 1-associated tumor cells, miR-10b targets the neurofi  bromin 
tumor suppressor, leading to activated RAS signaling. Color code: 
green, oncogenic and/or pro-metastatic factors; red, tumor-
suppressing and/or metastasis-suppressing factors.
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cancer cells without aﬀ   ecting their ability to grow as 
primary tumors – speciﬁ   cally, antagomir-10b blocked 
dissemination of cancer cells from the primary tumor, 
but did not aﬀ  ect late stages of the metastatic process 
after tumor cells had already disseminated. Furthermore, 
delivery of antagomir-10b to normal tissues did not have 
substantial toxicity [7]. Th  is work is the ﬁ  rst  report 
showing proof-of-principle that antagomirs can be 
eﬃ   ciently delivered to rapidly growing metastatic tumor 
cells  in vivo, can speciﬁ  cally silence the miRNA being 
targeted, and can prevent metastasis formation by other-
wise highly malignant cells. Th  e diﬀ  erential  eﬀ  ects  of 
antagomir-10b on primary mammary tumor growth, 
dissemination, and metastatic colonization could be 
explained by the previous ﬁ   ndings that miR-10b 
speciﬁ  cally promoted breast cancer cell migration and 
invasion but did not aﬀ  ect proliferation of these cells [6]. 
Th   is antagomir result also resembles the eﬀ  ect of shRNA-
mediated knockdown of Twist, which blocked intra-
vasation of 4T1 tumor cells but did not alter primary 
tumor growth [31].
In many breast cancer patients, disseminated, circulat-
ing tumor cells are readily detectable before surgery [32]. 
Th  ese disseminated tumor cells can later emerge at a 
secondary site where they grow into a macroscopic 
tumor (called metastatic recurrence). Th  e current neo-
adjuvant therapies used in the breast cancer clinic are 
mainly intended to shrink the primary disease in order to 
make the subsequent surgery more complete; however, 
these existing neoadjuvant therapies may not be eﬀ  ective 
in blocking metastatic dissemination (RJ Lee and TA 
Ince, personal communication).
Because the miR-10b antagomir prevents metastatic 
dissemination but does not aﬀ  ect the late stages of the 
metastatic process after tumor cells have already 
disseminated, the main promise for developing an agent 
such as antagomir-10b as a potential therapy would be 
whether it can be added during treatment starting in the 
early stages as a prophylactic therapy against future 
metastasis formation. Since antagomir-10b does not 
shrink a primary tumor, it should be combined with 
other anti-tumor drugs and/or surgical resection of the 
primary tumor as a neoadjuvant therapeutic strategy, 
which can be ﬁ  rst tested in preclinical models.
Preclinical studies are diﬀ  erent from clinical settings. 
Th  e 4T1 cell line used in the antagomir-10b study was 
derived from a subset of cancer cells present in the 
original tumor that are highly metastatic and express 
high levels of Twist and miR-10b, and thus is expected to 
respond to silencing of Twist or miR-10b. At the clinical 
level, as aforementioned, our current knowledge is that 
miR-10b is upregulated in some metastatic breast 
tumors. In contrast, miR-10b is expressed at very low 
levels in early-stage or nonmetastatic breast tumors 
[6,10]. Similarly, Twist has been found to be over-
expressed in advanced tumors that are metastatic and/or 
invasive, including invasive lobular breast carci  no  ma 
[31], inﬁ  ltrative gastric cancer [33], metastatic mela  noma 
[34], glioblastoma [35], the aggressive subtype of neuro-
blastoma [36], and spindle cell carcinoma of the head and 
neck [37]. Th   e obvious explanation is that upregulation of 
Twist and resulting activation of miR-10b expression 
occur late during primary tumor progression. What, 
then, is the rationale for giving the miR-10b antagomir to 
early-stage or nonmetastatic breast tumors, which 
express low levels of miR-10b?
It should be noted that all these expression analyses 
were carried out by northern blot or quantitative PCR on 
whole-tumor specimens. Only a small subset of primary 
tumor cells is probably responsive to stromal signals by 
upregulating Twist, resulting in activated expression of 
miR-10b. Whether a minor sub  population of cancer cells 
present in some of the early-stage or nonmetastatic 
breast tumors express high levels of Twist and miR-10b, 
utilizing in situ hybridization techniques, remains to be 
seen. Th  is expression could provide the rationale and 
selection criteria for treating early-stage or nonmetastatic 
breast tumors with the miR-10b antagomir, as part of the 
neoadjuvant regimen.
Conclusions
Th   e present review summarizes evidence for the growing 
implication of miR-10b miRNA in cancer progression, 
particularly metastatic progression of breast cancer. Th  e 
pro-metastatic function of miR-10b has been demon-
strated in diﬀ   erent xenograft models. Whether this 
Twist-induced miRNA plays a role in normal develop-
ment, and whether it is required for metastasis formation 
in mouse models of spontaneous breast cancer, remain to 
be determined.
Th   e miR-10b antagomir appears to be a starting point 
for the development of miRNA-based, anti-metastasis 
agents, and extensive analyses will be required to deter-
mine the eﬃ     cacy and safety of such agents by using 
multiple model systems. Because antagomir-10b does not 
shrink a primary tumor but instead stops its metastatic 
ability, it would be of interest to use the antagomir in 
combination with surgical resection to treat breast 
tumor-bearing mice and to determine whether this 
combination treatment can lead to both primary tumor 
removal and prevention from future metastatic relapse. 
Finally, it is important to develop selection criteria to 
identify clinical breast tumors that are expected to 
respond to silencing of miR-10b.
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